Feasibility and utility of applications of the common data model to multiple, disparate observational health databases

Journal of the American Medical Informatics Association

Volumn 22, Issue 3, 2015, Pages 553-564

  Voss, Erica A ^a   Makadia, Rupa ^a   Matcho, Amy ^a   Ma, Qianli ^a   Knoll, Chris ^a   Schuemie, Martijn ^a   DeFalco, Frank J ^a   Londhe, Ajit ^a   Zhu, Vivienne ^a   Ryan, Patrick B ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Controlled health services research; Database; Factual vocabulary; Medical informatics observational study

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; DATA BASE; EPIDEMIOLOGICAL DATA; FEASIBILITY STUDY; MEDICAL INFORMATION SYSTEM; MEDICAL TERMINOLOGY; MODEL; OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP COMMON DATA MODEL; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; STANDARDIZATION; COMPUTER PROGRAM; CONTROLLED VOCABULARY; EVALUATION STUDY; FACTUAL DATABASE; HEALTH SERVICES RESEARCH; HUMAN; STANDARDS;

DATABASES, FACTUAL; FEASIBILITY STUDIES; HEALTH SERVICES RESEARCH; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; SOFTWARE; VOCABULARY, CONTROLLED;

EID: 84940392979     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1093/jamia/ocu023     Document Type: Article

References (36)

1. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-337.
2. Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48(6):S114-S120.
3. Madigan D, Stang PE, Berlin JA, et al. A systematic statistical approach to evaluating evidence from observational studies. Ann Rev Stat Appl. 2014;1(1):11-39.
4. Psaty BM, Furberg CD. COX-2 inhibitors-lessons in drug safety. N Engl J Med. 2005;352 (11):1133-1135.
5. Reisinger SJ, Ryan PB, O'Hara DJ, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. JAMIA 2010;17 (6):652-662.
6. National Research Council. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: The National Academies Press; 2007.
7. Food and Drug Administration Amendments Act of 2007. US Government Printing Office Website. http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/html/PLAW-110publ85.htm. Accessed June 12, 2014.
8. FDA's Sentinel Initiative. US Food and Drug Administration Website. http://www.fda.gov/safety/FDAsSentinelInitiative/ucm2007250.htm. Accessed June 12, 2014.
9. Observational Medical Outcomes Partnership (OMOP). Observational Medical Outcomes Partnership Website. http://omop.org. Accessed June 12, 2014.
10. Observational Health Data Sciences and Informatics (OHDSI) Website. http://www.ohdsi.org. Accessed June 12, 2014.
11. Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Safety. 2011;20(1):1-11.
12. EU-ADR. EU-Adverse Drug Reactions Website. http://www.euadr-project.org. Accessed June 12, 2014.
13. OMOP Common Data Model (CDM). Observational Medical Outcomes Partnership Website. http://omop.org/CDM. Accessed June 13, 2014.
14. OMOP Vocabularies. Observational Medical Outcomes Partnership Website. http://omop.org/Vocabularies. Accessed June 13, 2014.
15. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600-606.
16. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. JAMIA. 2012;19(1):54-60.
17. Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. Med Care. 2012;50 Suppl:S60-S67.
18. Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645-651.
19. Madigan D, Ryan PB, Schuemie M. Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies. Ther Adv Drug Safety. 2013;4(2):53-62.
20. Ogunyemi OI, Meeker D, Kim HE, Ashish N, Farzaneh S, Boxwala A. Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems. Med Care. 2013;51 (8 Suppl 3):S45-S52.
21. Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401-4415.
22. Ryan PB, Stang PE, Overhage JM, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Safety. 2013;36(Suppl 1):S143-S158.
23. Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012;45(4):689-696.
24. WhiteRabbit [computer application]. GitHub Website. https://github.com/OHDSI/WhiteRabbit. Accessed June 13, 2014
25. Matcho A. OMOP Common Data Model (CDM, Version 4.0): Clinical Practice Research Datalink (CPRD) Mapping Specification. Washington, DC: Reagan-Udall Foundation for the FDA; Year of Publication: 2014. http://75.101.131.161/download/loadfile.php?docname1/4CPRD%20ETL. Accessed June 23, 2014.
26. Makadia R. OMOP Common Data Model (CDM, Version 4.0): ETL Mapping Specification Premier. Washington, DC: Reagan-Udall Foundation for the FDA; Year of Publication: 2014. http://75.101.131.161/download/loadfile.php?docname1/4Premier%20ETL. Accessed June 23, 2014.
27. Ma Q, Voss E. Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson Common Data Model (CDM, Version 4.0) ETL Mapping Specification for Optum Washington, DC: Reagan-Udall Foundation for the FDA; Year of Publication: 2014. http://75.101.131.161/download/loadfile.php?docname1/4OPTUM%20ETL. Accessed June 23, 2014.
28. Ma Q, Voss E. Johnson & Johnson Common Data Model (CDM, Version 4.0) ETL Mapping Specification for TRUVEN (CCAE and MDCR). Washington, DC: Reagan-Udall Foundation for the FDA; Year of Publication: 2014. http://75.101.131.161/download/loadfile.php?docname1/4CCAE%2FMDCR%20SAS%20ETL%20by%20Janssen. Accessed June 23, 2014.
29. Ma Q, Voss E. Johnson & Johnson Common Data Model (CDM, Version, 4.0) ETL Mapping Specification for TRUVEN (MDCD). Washington, DC: Reagan-Udall Foundation for the FDA; Year of Publication: 2014. http://75.101.131.161/download/loadfile.php?docname1/4MDCD%20SAS%20ETL%20by%20Janssen. Accessed June 23, 2014.
30. Ryan C, Joshua JG, Jennifer N, et al; US Food and Drug Administration. Mini-Sentinel Surveillance Plan: Mini-Sentinel prospective routine observational monitoring program tools (prompt): rivaroxaban surveillance. http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentinel_PROMPT_Rivaroxaban-Surveillance-Plan.pdf. Accessed June 23, 2014.
31. Matcho A, Ryan PB, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP Common Data Model. Drug Safety. 2014;37(11):945-959.
32. Makadia R, Ryan P. Transforming the Premier Perspective hospital database into the OMOP Common Data Model. eGEMs (Generating Evidence & Methods to improve patient outcomes). 2014;2(1)Article 15.
33. Weinstein RB, Schuemie MJ; Observation Medical Outcomes Partnership. Seasonality in acute liver Injury in healthcare claims data. http://omop.org/sites/default/files/34_Weinstein_ALI%20seasonality.pdf. Accessed June 23, 2014.
34. Fife D, Zhu V, Voss E, Levy-Clarke G, Ryan P. Exposure to oral fluoroquinolones and the risk of retinal detachment: retrospective analyses of two large healthcare databases. Drug Safety. 2014;37(3):171-182.
35. Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain. 2013;14(10):1227-1241.
36. Knoll CA, DeFalco FJ, Ryan PB; Observation Medical Outcomes Partnership. Applications of the OMOP Common Data Model for clinical trial feasibility assessment. http://omop.org/sites/default/files/04_Knoll_OMOP%20DM%20for%20Clincial%20Trial%20Feasibility%20Assessment.pdf. Accessed June 23, 2014.